Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Recruiting 26Active not recruiting 19Not yet recruiting 6Completed 3Terminated 1

Sponsor Class

OTHER 4NETWORK 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 4Anatomic Stage IV Breast Cancer AJCC v8 1Advanced HER2-positive Breast Cancer 1

Interventions

Specimen Handling 57Magnetic Resonance Spectroscopy 39Carboplatin 32Cyclophosphamide 29Gemcitabine 28Bevacizumab 24pembrolizumab 23Cisplatin 23Biopsy 23Paclitaxel 22Standard of Care 21Radiotherapy 21Drug Therapy 21fludarabine 20Injections 20Capecitabine 20venetoclax 19Oxaliplatin 19Nivolumab 18Interviews as Topic 17toripalimab 16Dexamethasone 16Blood Specimen Collection 16Radiosurgery 14tislelizumab 13cemiplimab 13anlotinib 13Azacitidine 13Pemetrexed 12Irinotecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Not yet recruiting × pertuzumab × 90 days × Clear all
NCT07578116 2026-05-27

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

SWOG Cancer Research Network

Phase 3 Not yet recruiting
562 enrolled
Breast

Anatomic Stage IV Breast Cancer AJCC v8

NCT07581795 2026-05-12

SPECTACLE

Fudan University

Phase 2 Not yet recruiting
140 enrolled
Breast

Advanced HER2-positive Breast Cancer

NCT07565324 2026-05-04

UC HER

National Taiwan University Hospital

Phase 2 Not yet recruiting
54 enrolled
Breast

Breast Neoplasms

NCT07545044 2026-04-22

A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer

Shanghai JMT-Bio Inc.

Phase 2 Not yet recruiting
60 enrolled
Breast

Breast Neoplasms

NCT07527806 2026-04-17

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Peking University Cancer Hospital & Institute

Phase 2 Not yet recruiting
156 enrolled
Breast

Breast Neoplasms

NCT07528898 2026-04-14

Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.

Hebei Medical University Fourth Hospital

Phase 2 Not yet recruiting
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡